Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 267% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- ROE of 129.5% — good return on equity
- Revenue growing at 6% annually
DAVITA INC. (DVA) is a Healthcare company operating in Services-Misc Health & Allied Services, NEC, listed on the NYSE , with a market capitalisation of $9.9 billion . Key value metrics: P/E ratio 13.6, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
DAVITA INC. — Fundamental Analysis Summary
DAVITA INC. (DVA) is currently trading 267% above its Graham Number of $40.35, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 13.6x.
On financial health, DVA shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and strong return on equity of 129.5% (sector average: -19.8%), and high leverage with a debt-to-equity ratio of 11.55.
StockPik's composite Value Score for DVA is 75/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
DVA shows revenue growing at 6% year-over-year, with earnings declining at 20%.